FDA-authorized Paxlovid by Pfizer offers no benefit to non-seniors

A study of over 100 thousand patients published in the New England Journal of Medicine on August 24, 2022, shows that oral protease inhibitor nirmatrelvir, used in combination with ritonavir under the brand name Paxlovid, offered no evidence of statistically reducing the rate of hospitalization from COVID among both treated and untreated patients 40 to […]

FDA authorizes Pfizer’s Paxlovid pill as first at-home COVID treatment

SILVER SPRINGS, MD, December 22, 2021 – Today, the Food and Drug Administration authorized Pfizer’s Paxlovid for adults and children ages 12 and older with a positive COVID-19 test and early symptoms who face the highest risks of hospitalization. Children eligible for the drug must weigh at least 88 pounds. Paxlovid, is an alternative treatment […]